In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.
about
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of AmericaStructural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC -LactamasesClinical management of infections caused by multidrug-resistant EnterobacteriaceaeNew β-lactamase inhibitors: a therapeutic renaissance in an MDR world.Ceftaroline fosamil: a brief clinical review.Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.In vivo activity of cefquinome against Escherichia coli in the thighs of neutropenic miceIn vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolatesClinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumoniaEfficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolatesAvibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitorEfficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model.Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-AvibactamSingle- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjectsHuman simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.Advances in MRSA drug discovery: where are we and where do we need to be?In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance studyIn vivo efficacy of humanized ceftaroline fosamil-avibactam exposures in a polymicrobial infection modelEfficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model.Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections.Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.Current strategies for the treatment of complicated intraabdominal infections.Escherichia coli sequence type 131: epidemiology and challenges in treatment.Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens.The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.In vitro microdialysis membrane efficiency of broad-spectrum antibiotics in combination and alone.Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.Periprosthetic joint infections: clinical and bench research.Diversity and Proliferation of Metallo-β-Lactamases: a Clarion Call for Clinically Effective Metallo-β-Lactamase InhibitorsDevelopment and Validation of Stability Indicating RP-HPLC Method for Estimation of Ceftaroline Fosamil in Bulk and Its Parenteral Dosage Forms
P2860
Q24601746-6FBE129F-6900-473B-8459-43E5A085AD87Q27676626-74E46A5D-D29E-47BC-B119-2A85DB9D84ECQ28246841-BF77E76A-5441-4629-AD00-2ACAE22A0C1EQ33622976-FA42C955-CC9D-4FB0-9736-45976E0631BBQ33939080-C9C66969-04D3-4694-AC81-B630CA11D3EAQ34058217-3BE8B614-47CA-4901-9EBA-2527C9060CA7Q34299028-49F47DB5-18CA-45BC-A78A-AEF2AB099E2DQ34596516-BA9D9E96-C1EE-49CB-834C-692A905B2ED7Q35191501-30084FAE-0206-4CAF-928D-E2899C4A9188Q35752997-DD7D3CA8-2754-4BCB-A89F-3DEFBF09D6F6Q35941308-EC75A1D0-930A-497D-8243-A1C527F9A016Q36122731-4894674C-EDE8-4834-817B-8D2D82C82176Q36396172-A464B093-6F08-4603-87D3-0CAF49C25ACCQ36396244-FC6009FD-CB7E-4CF8-89FA-B2B324A475F1Q36644679-5C0831E1-C90C-4328-986A-233720A2D848Q36667104-0AE9B516-19FD-49BC-86FE-0394FB724FECQ36969982-8A6D7C01-F038-424F-A42F-E5EBC057CC3EQ37112508-EEE59311-4B87-4F0E-A1C7-E96B273E87FAQ37263425-7D6C079E-84C9-4979-B515-3900971385DFQ37263439-CCB1B1DA-AB82-480E-B905-4AA0BB207A56Q37643614-5FBE7BA1-E9B2-4A87-AFDD-D5AB2498F238Q38006689-7233232A-8E94-4584-AF80-C7859A77BCB4Q38061168-981E9191-0126-44F0-8A2A-3A7BF19BBBBDQ38123247-CDCF50EC-F17E-4D4D-A527-E461247CCE2CQ38201515-9034C87A-2B7C-4EBC-AD1E-CA50F345753AQ38262205-C12E1D84-C6D9-49D7-9961-41B9E659D510Q38892589-8DA9216A-C0B0-4D35-ABB1-BE155A95EDABQ40389902-0A32BF7F-2DF9-409A-945F-A2E73B3EDAD0Q40517120-2F795A39-FF3E-4FC5-822B-3D1B445806CDQ46267269-17221FA9-9852-4123-900B-2014016635A6Q53663173-655CDA1E-20AD-40DD-B115-37508BBC144FQ58641878-707C5761-2AD6-4FA5-BFA9-0FDAE1C3C92FQ58995336-3973EE08-7709-443B-902A-41F5C10140E5
P2860
In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
In vivo efficacy of a human-si ...... -producing Enterobacteriaceae.
@ast
In vivo efficacy of a human-si ...... -producing Enterobacteriaceae.
@en
type
label
In vivo efficacy of a human-si ...... -producing Enterobacteriaceae.
@ast
In vivo efficacy of a human-si ...... -producing Enterobacteriaceae.
@en
prefLabel
In vivo efficacy of a human-si ...... -producing Enterobacteriaceae.
@ast
In vivo efficacy of a human-si ...... -producing Enterobacteriaceae.
@en
P2093
P2860
P356
P1476
In vivo efficacy of a human-si ...... -producing Enterobacteriaceae.
@en
P2093
David P Nicolau
Dora E Wiskirchen
Gregory Williams
Guilherme H Furtado
Jared L Crandon
P2860
P304
P356
10.1128/AAC.00024-11
P407
P577
2011-04-25T00:00:00Z